SenoRx Inc.

Aliso Viejo, Calif. • 949-362-4800 •

Exchange and Ticker: Nasdaq: SENO

Filing Range: 5.5M shares @ $11.00 to $13.00

Offering Price: $8.00

Close on First Day: $8.18

Offering Size: $44.00M

Shares Outstanding: 14,980,572

Underwriters: Banc of America Securities LLC/ Citigroup

Co-managers: SG Cowen Securities Corp./ Canaccord Adams

Company Counsel: Wilson Sonsini Goodrich & Rosati

Manager Counsel: Cleary Gottlieb Steen & Hamilton

Auditor: Deloitte & Touche LLP

Market Capitalization on 3/31/07: $122.69M

Close price at current month end: $8.19


Develops, manufactures and sells minimally invasive medical devices for the diagnosis of breast cancer. Our initial product focus has been biopsy systems and breast tissue markers. Company is also developing products for use in the treatment of breast cancer that will seek to commercialize, subject to receipt of required regulatory approvals, including a radiation balloon for localized radiation therapy and cutting devices for both excision of tissue and cosmetic reconstruction. Competitors include Johnson & Johnson, C.R. Bard, Suros Surgical Systems and Cytyc. SenoRx was formerly known as BiopSolation Medical Inc.


De Novo Ventures, Domain Associates, Mayfield Fund, Medicus Venture Partners, MPM Capital, Protostar Partners, RB Webber & Co., SunAmerica Ventures and Tyco Capital.

Source: Thomson Financial